Edition:
United Kingdom

Sawai Pharmaceutical Co Ltd (4555.T)

4555.T on Tokyo Stock Exchange

6,090JPY
21 Nov 2017
Change (% chg)

-- (--)
Prev Close
¥6,090
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
187,622
52-wk High
¥6,700
52-wk Low
¥5,700

Latest Key Developments (Source: Significant Developments)

Sawai Pharmaceutical to sell 20 pct stake in SAWAI AMERICA for $211 mln
Monday, 13 Nov 2017 

Nov 13(Reuters) - Sawai Pharmaceutical Co Ltd <4555.T>:Says it plans to sell 20 percent stake in a wholly owned U.S.-based unit SAWAI AMERICA INC to Sumitomo Corporation of Americas, a wholly owned unit of SUMITOMO CORPORATION <<<8053.T>>>, for $211 million (23.2 billion yen).Transaction will be completed as of the end of March 2018.  Full Article

Upsher-Smith says parent co to manufacture migraine medication in Japan With AstraZeneca
Monday, 30 Oct 2017 

Oct 30 (Reuters) - Upsher-Smith Laboratories LLC::Upsher-Smith Laboratories says co's parent Sawai Pharmaceutical entered agreement with AstraZeneca to manufacture & market migraine medication in Japan​.Upsher-Smith Laboratories​ - agreement is to ‍manufacture, market Zomig (zolmitriptan) Tablets 2.5 mg & Zomig (zolmitriptan) Rapid Melt (RM) Tablets 2.5 mg.Upsher-Smith Labs - ‍under agreement, Sawai expected to take manufacturing, marketing of Zomig​ products in Japan by mid-2018 from AstraZeneca K.K.  Full Article

Sawai Pharmaceutical gearing up to sell generic drugs in U.S. - Nikkei<4555.T>
Thursday, 26 May 2016 

Nikkei : Is gearing up to sell generic drugs in the U.S. - Nikkei . Expects to win FDA approval to sell generic version of cholesterol drug Pitavastatin starting between April and September 2017 - Nikkei . Also plans to have three other generics in the pipeline for FDA approval in the fiscal year ending in March 2018 - Nikkei . Pharmaceutical's move into U.S. and higher capacity likely will spur co to raise its group sales target for year ending in March 2018 - Nikkei .  Full Article

REFILE-TABLE-Sawai Pharmaceutical- 6-MTH group results

(Adds company forecast. Accounting policy for forecast is IFRS) Nov 13 (Reuters)- Sawai Pharmaceutical Co Ltd CONSOLIDATED FINANCIAL HIGHLIGHTS (in billions of yen unless specified) 6 months ended 6 months ended Year to Sep 30, 2017 Sep 30, 2016 Mar 31, 2018 LATEST YEAR-AGO LATEST RESULTS RESULTS FORECAST Sales 70.76 65.42